ALEXION PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization
Impairment of intangible assets
Change in fair value of contingent consideration
Payments of contingent consideration
Share-based compensation expense
Non-cash expense for acquired IPR&D
Deferred tax (benefit) expense
Change in excess tax benefit from stock options
Unrealized foreign currency (gain) loss
Unrealized loss (gain) on forward contracts
Unrealized loss (gain) on strategic equity investments
Gain on sale of strategic equity investments
Gain on sale of asset
Gain on modification of purchase option
Gain on derecognition of Portola strategic equity investment
Inventory obsolescence charge
Other
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable
Inventories
Prepaid expenses, right of use operating assets and other assets
Accounts payable, accrued expenses, lease liabilities and other liabilities
Deferred revenue

Net cash provided by operating activities
Cash flows from investing activities:
Purchases of available-for-sale debt securities
Proceeds from maturity or sale of available-for-sale debt securities
Purchases of mutual funds related to nonqualified deferred compensation plan
Proceeds from sale of mutual funds related to nonqualified deferred compensation plan
Purchases of property, plant and equipment
Payments for acquisitions of businesses, net of cash and restricted cash acquired
Purchases of strategic equity investments and options
Proceeds from sale of strategic equity investments
Purchases of intangible assets
Other
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Debt issuance costs
Proceeds from revolving credit facility
Payments on revolving credit facility
Proceeds from term loan
Payments on term loan
Equity issuance costs for shares issued in connection with acquisition of business
Change in excess tax benefit from stock options
Repurchase of common stock
Net proceeds from issuance of stock under share-based compensation arrangements
Payments of contingent consideration
Repayment of development-related grants
Other
Net cash used in financing activities

Effect of exchange rate changes on cash and cash equivalents and restricted cash
Net change in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of period
Cash and cash equivalents and restricted cash at end of period
Supplemental cash flow disclosures:
Cash paid for interest (net of amounts capitalized)
Cash paid for income taxes
Supplemental non-cash disclosures from investing and financing activities:
Fair value of strategic investment and purchase option acquired, less upfront cash paid
Operating ROU lease assets obtained in exchange for operating lease liabilities
Capitalization of construction costs related to facility lease obligations
Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets
Contingent consideration issued in acquisition
Fair value of equity shares in Portola settled at closing of the acquisition
Fair value of replacement equity awards issued to Portola employees attributable to the pre-combination period
Exchange of intellectual property rights for equity shares in Inozyme
Cash and cash equivalents
Restricted cash included in other current assets
Restricted cash included in other noncurrent assets

Comments